Navigation Links
Preliminary Lineup Set for 4th Annual Stem Cell Summit
Date:8/12/2008

Stem Cell Company Executives, Scientists and Investors Will Gather Feb. 17

in New York City to Discuss Commercialization of Stem Cell Products

PHILADELPHIA, Aug. 12 /PRNewswire/ -- RRY Publications today announced the preliminary lineup of presenters for the 4th Annual Stem Cell Summit, the premier gathering of stem cell company executives, scientists and investors to focus on the commercialization of stem cell products. The Stem Cell Summit is an intensive one-day event that allows attendees to explore the therapeutic applications of stem cells, the successful path to stem cell product commercialization, and the latest investment opportunities within this marketplace.

The 4th Annual Stem Cell Summit features 35 corporate presenters, keynote speaker Dr. Arnold Caplan, Ph.D., and a scientific panel discussion. It will take place on February 17, 2009, at Bridgewaters in the heart of New York City's historic South Street Seaport.

Confirmed presenting stem cell companies include:

3DM, Inc. Incell Corporation, LLC

Aastrom Biosciences, Inc. MaxCyte, Inc.

Aldagen, Inc. Moraga Biotechnology Corporation

AllCells, LLC Neuronyx, Inc.

Arteriocyte, Inc. Novocell, Inc.

BioE Corp. NuVasive, Inc.

California Stem Cell, Inc. Osiris Therapeutics, Inc.

Cellerix, S.A. Progenitor Cell Therapy, Inc.

Cognate BioServices, Inc. Stemagen

Cytori Therapeutics, Inc. Stemina, Inc.

Gamida Cell Ltd. TiGenix NV

Geron Corp. Tissue Genesis, Inc.

Harvest Technologies Corp. Vet-Stem, Inc.

Histogen, Inc.

In addition to the company and product overviews, Robin R. Young, CFA, the leading medical technologies analyst in the United States with over 25 years' experience in the cardiovascular, orthopedic and biomaterials industries and the award-winning president and organizer of the annual Stem Cell Summit, will deliver his updated 10-year market forecast for the industry.

"2008 has already been a record-breaking year for stem cell technologies with two of the largest purchase contracts ever recorded - one for more than $200 million from the U.S. government and another for $85 million to purchase a single stem cell product line," said Robin Young. "There is little doubt that 2009 will be the year that stem cell companies and technologies cross the $100 million in annual revenues line and become a billion-dollar valuation industry."

4th Annual Stem Cell Summit Facts at a Glance

What: 2009's Premier Gathering of Stem Cell Company Executives,

Scientists and Investors

When: February 17, 2009

Where: Bridgewaters

11 Fulton Street

New York City

Who: The Stem Cell Summit is organized by Robin R. Young, CFA and RRY

Publications, LLC.

Admission: $950 early bird registration by November 30, 2008

$1,200 advance registration (December 1, 2008 - January 31,

2009)

$1,500 (February 1 - 17, 2009)

Information: For more information on presentation or sponsorship

opportunities, call Lisa Carpenter at 877-817-6450 or send an

email to lisa@ryortho.com . Additional information, including

attendee registration details, is available at

http://www.stemcellsummit.com

Contacts: Lisa Carpenter

RRY Publications, LLC

877-817-6450

lisa@ryortho.com


'/>"/>
SOURCE RRY Publications
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sunrise Updates Date and Time of Conference Call to Discuss 2007 Financial Results and Second-Quarter 2008 Preliminary Selected Financial and Operating Data
2. Misys Announces Preliminary Results for the Year Ended 31 May 2008
3. Longs Reports Preliminary June Retail Drug Store Sales
4. Cardiogenesis Announces Preliminary Results Combining TMR + Platelet Rich Plasma (PRP)
5. NightHawk Radiology Holdings, Inc. Announces Preliminary Results of Its Tender Offer; NightHawk Expects to Purchase 2,367,438 Shares of Its Common Stock at $8.05 per Share
6. Longs Reports Preliminary May Retail Drug Store Sales
7. AVMA Declares Preliminary Victory on Farm Bill Provisions
8. NBTY Announces Preliminary Unaudited Net Sales Results for April 2008
9. ENDO 08 preliminary news conference and webcast schedule
10. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
11. WebMD Provides Preliminary First Quarter Results and Updates Financial Guidance for 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... The doctors at Wall Centre Dental are ... dental fear and require sedation to receive dental care. The doctors offer three treatment ... from hygienic cleanings to oral surgery, at their dental office in Vancouver. Wall Centre ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients ... that achieves results in a fraction of the time as traditional braces – ... Significance Dental Specialists, now offers this revolutionary treatment with or without a referral. ...
(Date:4/25/2017)... ... April 25, 2017 , ... As Spring reignites vigilance ... research related to Zika virus during pregnancy, as well as other prenatal exposures ... science. , The Teratology Society is an international and multidisciplinary ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving multi-billion dollar ... shops –can’t help but be heartened by the industry’s current surge. But another thing ... as “skunk smell.” At last they can simply, safely and effectively end their ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a leading provider of ... management module. Using this new feature, sleep physicians can now predict the likelihood ... positive airway pressure (CPAP), oral, or other forms of sleep apnea therapy. The ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Injectables Market and Increasing Usage of Complex Biologics during the Forecast ... ... USD 20 Billion in 2015 to around USD 26 Billion by ... Driven by Rapidly Expanding Injectables Market and Increasing Usage of Complex ...
(Date:4/20/2017)... 2017   ZappRx, Inc ., a digital health company ... today announced it closed $25 million in Series B funding ... based in Seattle that is part ... The Series B round included participation from SR One ... GV (formerly Google Ventures). As part of the ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology: